CA - Knight Therapeutics reports Q1 earnings; updates FY23 outlook
2023-05-11 07:42:35 ET
- Knight Therapeutics press release ( OTCPK:KHTRF ): Q1 GAAP EPS of -C$0.04.
- Revenue of C$82.6M (+29.4% Y/Y).
- Gross margin of C$40.76M or 49% compared to C$32.48M or 51% in the same period in prior year.
- Adjusted EBITDA was C$18.24M, an increase of 37% over the same period in prior year.
- Adjusted EBITDA per share of C$0.17, an increase of 45% over the same period in prior year.
- Guidance: For fiscal 2023, Knight has updated its guidance and expects to generate $300 to $320 million in revenue, an increase of $20 million on the lower and upper range. The adjusted EBITDA, as a percentage of revenues is expected to be between 14% to 15% of revenues.
For further details see:
Knight Therapeutics reports Q1 earnings; updates FY23 outlook